Form 4: BioLargo Director Acquires Options as Compensation for Board Service
SEC Form 4 Filing
Christina Elaine Bray, a director of BioLargo, Inc., acquired options to purchase 73,529 shares of common stock as compensation for board service.
Summary
- On June 30, 2024, Christina Elaine Bray, a director of BioLargo, Inc., acquired an option to purchase 73,529 shares of common stock.
- The options were granted as payment for $18,750 in fees for board services during the most recent quarterly period.
- The exercise price of the options is $0.255 per share.
- The options were issued under the company's 2024 Equity Incentive Plan.
- Following the transaction, Ms. Bray directly owns options to purchase 712,811 shares of BioLargo common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an option grant to a director as part of their compensation. There are no explicit positive or negative implications.
Positives
- The issuance of options as compensation aligns the director's interests with those of the shareholders.
- The equity incentive plan is being utilized to reward board members.
Industry Context
Granting stock options to board members is a common practice to align their interests with the long-term success of the company and its shareholders. This is a standard form 4 filing related to insider transactions.
Comparison to Industry Standards
- Stock option grants to directors are a common practice across various industries, particularly in smaller companies or those seeking to conserve cash.
- The size of the grant (73,529 options) and the exercise price ($0.255) would need to be compared to similar companies in the same sector to determine if it is within industry norms.
- Companies like Aqua Metals or OriginClear, which operate in related fields, could be used as benchmarks for comparing executive compensation and equity grants.
Related Party Transactions
- The option grant to Christina Elaine Bray is a related party transaction as she is a director of BioLargo, Inc.
Stakeholder Impact
- The option grant could potentially dilute existing shareholders if the options are exercised.
- The grant incentivizes the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Date of Limited Power of Attorney for Section 16 Reporting Obligations |
| 2024-06-30 | Date of the option grant to Christina Elaine Bray |
| 2024-06-30 | Options exercisable date |
| 2024-06-30 | Transaction Date |
| 2024-06-30 | Options Expiration Date |
| 2024-07-01 | Date of signature of the report by attorney-in-fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.